TerminatedNCT03838484

Effects of Transdermal Nicotine on Response Inhibition to Emotional Cues in Schizophrenia

Medication studyAges 18–65United States

The study in practice

Understand this study

Listed age limits: 18 years to 65 years.

Listed locations: Nashville, United StatesSee all locations and recruitment
Activities: Medication described in the protocol · Placebo described in the protocol; its role is not resolved here
Compensation: Payment and expense reimbursement have not been verified.

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Study start dateStarted: May 10, 2019

Recruitment status: Terminated
Enrollment listed in the registry: 18
Sponsor: Vanderbilt University Medical Center
Sponsor type: Hospital / academic medical center
Study type: Drug
Intervention type: Medication / drug
Study phase: Not clearly listed
Locations: United States
Age range: From 18 Years to 65 Years
Official registry ID: NCT03838484
Official title: Show the full official title
Effects of Transdermal Nicotine on Response Inhibition to Emotional Cues in Schizophrenia

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Study ID: NCT03838484. We help you review the study, but cannot decide medical eligibility.

Terminated

Nashville

A listed location does not confirm current availability.

FAQ

Who is behind this study?

The study sponsor is Vanderbilt University Medical Center, a hospital or academic medical center.

Does this study involve medication?

Yes. The study involves medication, including Nicotine Patch, 7 Mg/24 Hr and Placebo patch.

Who can participate?

Listed age limits: 18 years to 65 years.

Is this study still recruiting?

The registry lists this study as terminated.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.